Lisa Bean, MD
Gynecologic Oncology · Calexico, CANPI 1760782817
Payments from drug & device makers
What this record shows
This record is dominated by education: $4,500 of the $5,375 with a category attached, or 83.7%. Intuitive Surgical accounts for 89.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $4,904 and has fallen 97.3% since, to $134 in 2025.
Across 33 payments — averaging $162.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- AbbVie$119
- AstraZeneca$118
- Hologic Sales And Service, LLC$80
- Bayer$64
- Aspira Women's Health Inc$49
- plus $136 from 5 others
What the payments were for
- Food & beverage$87516%
- Education$4,50084%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $4,809 |
| AbbVie | 7 | $119 |
| AstraZeneca | 1 | $118 |
| Hologic Sales And Service, LLC | 4 | $80 |
| Bayer | 4 | $64 |
| Aspira Women's Health Inc | 3 | $49 |
| Shield Therapeutics Inc | 1 | $44 |
| Organon | 1 | $33 |
| Astellas Pharma US Inc | 1 | $31 |
| Amarin Pharma, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$4,500
- FARXIGA$118
- Da Vinci Surgical System$116
How this compares
$5,375 in reported general payments places this provider in the 70th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 16 | $1,356 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Calexico
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
- Oliver DorigoStanford$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.